Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002488 | 0.87 | FAAH (0.58) | PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL5698709 | 0.84 | PTGS2 (0.75) | PTGS2PTGS1FAAHKCNH2ALDH1A1 | |
| SCHEMBL1004965 | 0.82 | FAAH (0.46) | PTGS2PTGS1FAAHKCNH2TP53 | |
| SCHEMBL8553156 | 0.80 | PTGS2 (0.68) | PTGS2PTGS1FAAHKCNH2ALDH1A1 | |
| SCHEMBL213979 | 0.80 | PTGS2 (0.68) | PTGS2PTGS1FAAHKCNH2ALDH1A1 | |
| SCHEMBL7504194 | 0.80 | PTGS2 (0.68) | PTGS2PTGS1FAAHKCNH2ALDH1A1 | |
| SCHEMBL1002617 | 0.78 | USP1 (0.42) | PTGS2PTGS1FAAHKCNH2TP53 | |
| SCHEMBL14849633 | 0.78 | MAPK14 (0.58) | CSNK1A1CSNK1DMAPK11MAPK14 | |
| SCHEMBL6050889 | 0.76 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL7944018 | 0.75 | MAPK13 (0.52) | PTGS1TP53MAPTALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2321288-B1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8673941-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673941-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673941-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| EP-2528603-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS | Merck Sharp & Dohme Corp. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011094209-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | PTGS2 224/4885PTGS1 131/4885FAAH 1/4885 |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | PTGS2 224/4885PTGS1 131/4885FAAH 1/4885 |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | PTGS2 216/4885PTGS1 122/4885FAAH 1/4885 |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | PTGS2 40/4885PTGS1 18/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.